Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, welcome Dr. Takahiro Suzuki to discuss his JACC paper, "Blood Pressure After Changes in Light-to-Moderate Alcohol Consumption in Women and Men: Longitudinal Japanese Annual Checkup Analysis." Using a two-cohort design—cessation among habitual drinkers and initiation among nondrinkers—the study demonstrates dose-dependent blood pressure effects when alcohol intake is reduced or begun, and importantly fills a major evidence gap for women and for light-to-moderate drinking, areas long underrepresented in prior research. These timely findings challenge assumptions about "safe" drinking levels and inform evolving hypertension guidelines and lifestyle counseling.

Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Satoshi Shoji, MD welcome Dr. Keishi Ichikawa, MD (Lundquist Institute at Harbor–UCLA) to discuss his JACC: Cardiovascular Imaging study from the Miami Heart Study, defining the population norms of coronary plaque using AI-based coronary CT angiography. In 2,301 asymptomatic adults, AI detected plaque in nearly 9 out of 10 individuals —providing age- and sex-specific nomograms for calcified and noncalcified plaque. The episode explores how these data move beyond calcium scoring, reveal "hidden" plaque burden, and lay the groundwork for future preventive strategies and risk stratification in truly asymptomatic populations.

Hosts Mitsuaki Sawano, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD welcome Prof. Yoshinobu Onuma (University of Galway)—Last Author of the ARC Position Statement—along with guest commentators Prof. Ken Kozuma (Teikyo University) and Dr. Taku Asano (St. Luke's International Hospital) to discuss the evolving role of drug-coated balloons (DCBs) in coronary intervention. The conversation highlights key insights from the ARC document, including DCB technology classifications, drug and coating differences, and the essential role of optimal lesion preparation, while outlining evidence-based indications across ISR, de novo lesions, bifurcations, ACS, diabetes, and high-bleeding-risk patients. The episode underscores why DCBs are not a class effect and how "leave nothing behind" strategies may shape the future of PCI.